Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include common findings: Brain shrinkage (cerebral atrophy) and Progressive loss of mental abilities (dementia). 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Brain shrinkage (cerebral atrophy), Parkinsonism, Progressive loss of mental abilities (dementia) |
Biomarker and diagnostic research for amyotrophic lateral sclerosis-parkinsonism-dementia complex has been reported in the published literature.
Phenotype severity distribution: 2 common features.
No clinical trials have been registered for amyotrophic lateral sclerosis-parkinsonism-dementia complex.
170 publications have been identified in PubMed for amyotrophic lateral sclerosis-parkinsonism-dementia complex. Research spans Review / Meta-Analysis (42%), Basic Science / Preclinical (21%), and Case Report / Case Series (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 72 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:40 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Muscles
3 |
Brain shrinkage (cerebral atrophy), Muscle spasm, Muscle weakness |
Laboratory research |
36 |
21% |
Patient case studies | 21 | 12% |
Disease patterns and progression | 21 | 12% |
Clinical study results | 7 | 4% |
Testing and diagnosis research | 5 | 3% |
New treatment approaches | 5 | 3% |
Other research | 3 | 2% |
Li H (2026). [PMID: 41643295](https://pubmed.ncbi.nlm.nih.gov/41643295/). *Arch Gerontol Geriatr*. [Epidemiology / Natural History]
Frota TQ (2026). [PMID: 41823883](https://pubmed.ncbi.nlm.nih.gov/41823883/). *Lupus*. [Review / Meta-Analysis]
Bhartiya D (2026). [PMID: 41779358](https://pubmed.ncbi.nlm.nih.gov/41779358/). *Stem Cell Rev Rep*. [Review / Meta-Analysis]
Simão S (2026). [PMID: 41396689](https://pubmed.ncbi.nlm.nih.gov/41396689/). *Redox Rep*. [Review / Meta-Analysis]
David C (2026). [PMID: 41395910](https://pubmed.ncbi.nlm.nih.gov/41395910/). *Ann Rheum Dis*. [Epidemiology / Natural History]
Buel KL (2026). [PMID: 41569909](https://pubmed.ncbi.nlm.nih.gov/41569909/). *FP Essent*. [Review / Meta-Analysis]
David C (2026). [PMID: 41805977](https://pubmed.ncbi.nlm.nih.gov/41805977/). *J Exp Med*. [Basic Science / Preclinical]
Smith RS (2026). [PMID: 41914024](https://pubmed.ncbi.nlm.nih.gov/41914024/). *Dis Model Mech*. [Review / Meta-Analysis]
Archambeaud A (2026). [PMID: 41056436](https://pubmed.ncbi.nlm.nih.gov/41056436/). *Rheumatology (Oxford)*. [Review / Meta-Analysis]
Dupré R (2026). [PMID: 40998734](https://pubmed.ncbi.nlm.nih.gov/40998734/). *Semin Ophthalmol*. [Review / Meta-Analysis]